Evidence map›Paper›PMID 41428767›Full record

ArticleBioscience reports2026

Design, synthesis, and anticancer activity of novel isocryptolepine 'aza' type acyl thiourea derivatives via combined experimental and computational approach.

Ammara Fayyaz, Syeda Abida Ejaz, Atteeque Ahmed, Pervaiz Ali Channar, Saira Afzal, Rabail Ujan, Aamer Saeed, Rifhat Bibi, Bshra A Alsfouk, Qamar Abbas and 3 more

Abstract read
In one paragraph

Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Synthesis, structure and computational study ofActa crystallographica. Section E, Crystallographic communications · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ammara FayyazDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, 63100, Pakistan.
Syeda Abida EjazDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, 63100, Pakistan.ORCID 0000-0002-8516-7234
Atteeque AhmedSulaiman Bin Abdullah Aba Al-Khail-Centre for Interdisciplinary Research in Basic Sciences (SA-CIRBS), International Islamic University, Islamabad, 44000, Pakistan.
Pervaiz Ali ChannarDepartment of Basic Science and Humanities, Faculty of Basic and Allied Sciences, Dawood University of Engineering and Technology, Karachi, 74800, Pakistan.ORCID 0000-0002-0748-0129
Saira AfzalFaculty of Pharmacy, The University of Lahore, Lahore, Pakistan.
Rabail UjanDepartment of MRC Liaquat, University of Medical & Health Sciences Jamshoro, Pakistan.
Aamer SaeedDepartment of Chemistry, Quaid-I-Azam University, Islamabad, 45320, Pakistan.ORCID 0000-0002-7112-9296
Rifhat BibiFatima Jinnah Women University Rawalpindi, Rawalpindi, 46000, Pakistan.
Bshra A AlsfoukDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Qamar AbbasDepartment of Biology, College of Science, University of Bahrain, Sakhir, 32038, Bahrain.
Reshma SahitoDepartment of Zoology University of Sindh, Jamshoro, Pakistan.
Michael BolteDepartment Chemie, Institut fuer Anorganische ChemieJ.-W.-Goethe-UniversitaetMax-von-Laue-Str. 7D-60438 Frankfurt/Main, Germany.
Tuncer HökelekDepartment of Physics, Faculty of Engineering, Hacettepe University, Beytepe-Ankara, Ankara, 06800, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To identify novel tyrosinase inhibitors, a series of isocryptolepine 'aza' type acyl thiourea analogs (6a-6h) were designed and synthesized using a multistep strategy. Spectroscopic methods including FTIR, UV-vis, 1H NMR, 13C NMR, and EI-MS were utilized for detailed analysis of compounds. Their tyrosinase inhibitory activities were evaluated in vitro, demonstrating superior potency compared with kojic acid (IC50 = 16.83 ± 1.162 μM). The synthesized compounds exhibited IC50 values ranging from 0.832 ± 0.03 to 7.945 ± 0.63 μM, with compound 6g emerging as the most potent inhibitor (IC50 = 0.832 ± 0.03 μM). Kinetic studies revealed competitive inhibition by compound 6g, highlighting its potential as a lead candidate for treating tyrosinase-mediated hyperpigmentation. Additional evaluations showed that these compounds also effectively inhibited other enzymes involved in cancer progression, indicating their broad therapeutic potential. Molecular modeling studies against the tyrosinase enzyme (PDB: 4OUA) confirmed strong binding interactions, while structure-activity relationship analyses provided insights into their inhibitory mechanisms. Geometry optimization of the compounds, supporting their favorable molecular properties. Drug-likeness evaluations further validated the potential of these analogs as promising anti-tyrosinase agents. Overall, this study establishes compound 6g and its analogs as compelling candidates for further development in hyperpigmentation and cancer therapeutics.

Indexed as

Antineoplastic AgentsDrug DesignEnzyme InhibitorsMonophenol MonooxygenaseThioureaCell Line, TumorHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsMonophenol MonooxygenaseThioureaacyl thioureahyperpigmentationisocryptolepinekinetic studiesmolecular modelingstructure–activity relationshiptyrosinase inhibitors

Identifiers

PMID41428767
PMCPMC12863032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.